logo
logo
REGENXBIO Inc.

REGENXBIO Inc.

NASDAQ•RGNX
CEO: Mr. Curran M. Simpson M.S.
セクター: Healthcare
業種: Biotechnology
上場日: 2015-09-17
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
連絡先情報
9804 Medical Center Drive, Rockville, MD, 20850, United States
240-552-8181
www.regenxbio.com
時価総額
$407.01M
PER (TTM)
-2.3
19.5
配当利回り
--
52週高値
$16.19
52週安値
$5.04
52週レンジ
27%
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$29.73M+22.88%
直近4四半期の推移

EPS

-$1.20+2.56%
直近4四半期の推移

フリーCF

-$56.45M+38.11%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Surge Total revenues reached $140.104M for nine months, up $77.976M, driven by Nippon Shinyaku upfront fee recognition.
Royalty Revenue Nearly Doubles License/royalty revenue hit $129.119M for nine months, up $67.947M, primarily from Zolgensma royalties.
Net Loss Significantly Narrows Nine-month net loss improved to $(126.729M), representing a favorable change of $49.187M versus prior period.
Cash Position Strengthened Cash, equivalents, and securities totaled $302.0M, bolstered by recent financing and collaboration proceeds.

リスク要因

High Cumulative Losses Accumulated deficit reached $1.06B; profitability depends heavily on successful product approval and commercialization.
Rising R&D Investment R&D expenses rose $10.546M to $168.688M for nine months, driven by manufacturing and clinical supply costs.
GSK Sublicense Fee Dispute Company disputes GSK claim regarding sublicense fees; no loss estimated, but legal uncertainty remains for operations.
Future Capital Requirements Expect significant additional capital needed to fund operations for several years before achieving recurring profitability.

見通し

RGX-314 Pivotal Data Expected ABBV-RGX-314 pivotal trial enrollment complete; expect sharing of topline data globally in fourth quarter 2026.
RGX-202 BLA Submission RGX-202 BLA submission anticipated mid-2026 via accelerated pathway following imminent Process Performance Qualification completion.
RGX-121 Approval Timeline RGX-121 BLA review timeline extended to February 8, 2026, following FDA request for 12-month clinical data.
New Financing Strategy Plan to secure significant additional capital through equity offerings, debt financings, or strategic alliances for operations.

同業比較

売上高 (TTM)

REGENXBIO Inc.RGNX
$161.32M
+91.3%
Gossamer Bio, Inc.GOSS
$44.05M
-58.2%
Bicycle Therapeutics plcBCYC
$28.34M
-23.2%

粗利益率 (最新四半期)

Bicycle Therapeutics plcBCYC
100.0%
+1705.8pp
Gossamer Bio, Inc.GOSS
100.0%
+0.0pp
Absci CorporationABSI
100.0%
+197.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
OLMA$1.78B-12.9-41.5%1.3%
CRVS$1.47B-96.1-25.8%1.3%
MLTX$1.24B-5.3-56.2%18.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
11.9%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月12日
|
EPS:-$0.99
|
売上高:-
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $29.73M+22.9%
    |
    EPS: $-1.20+2.6%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $21.36M-4.2%
    |
    EPS: $-1.38+31.4%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月12日|
    売上高: $89.01M+469.8%
    |
    EPS: $0.12-108.7%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月13日|
    売上高: $83.33M-7.7%
    |
    EPS: $-4.59+23.8%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月6日|
    売上高: $24.20M-16.3%
    |
    EPS: $-1.17-17.0%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月1日|
    売上高: $22.30M+11.6%
    |
    EPS: $-1.05-36.7%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月8日|
    売上高: $15.62M-18.4%
    |
    EPS: $-1.38-14.3%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月27日|
    売上高: $90.24M-19.9%
    |
    EPS: $-6.02+7.4%
    予想を下回る